NCT00724789View on ClinicalTrials.gov

Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED)

CompletedOBSERVATIONAL
Enrollment

2,066

Participants

Timeline

Start Date

November 30, 2000

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
PregnancyNeonates
Interventions
DRUG

ganirelix

Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy

DRUG

GnRH agonist

Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00724789 - Monitor the Incidence of Congenital Malformations in Infants of Women Who Have Been Treated With Ganirelix (Orgalutran®)(Study 38644)(P05966)(COMPLETED) | Biotech Hunter | Biotech Hunter